Zobrazeno 1 - 10
of 1 236
pro vyhledávání: '"Steger Hartmann T"'
Autor:
Steger-Hartmann T; Bayer AG, Pharmaceuticals, Berlin, Germany., Sanz F; Universitat Pompeu Fabra, Hospital del Mar Research Institue, Barcelona, Spain., Bringezu F; Merck Healthcare KGaA, Darmstadt, Germany., Soininen I; SYNAPSE Research Management Partners SL, Madrid, Spain.
Publikováno v:
Toxicologic pathology [Toxicol Pathol] 2024 Dec 12, pp. 1926233241303906. Date of Electronic Publication: 2024 Dec 12.
Autor:
Sanz F, Pognan F, Steger-Hartmann T, Díaz C, Asakura S, Amberg A, Bécourt-Lhote N, Blomberg N, Bosc N, Briggs K, Bringezu F, Brulle-Wohlhueter C, Brunak S, Bueters R, Callegaro G, Capella-Gutierrez S, Centeno E, Corvi J, Cronin MTD, Drew P, Duchateau-Nguyen G, Ecker GF, Escher S, Felix E, Ferreiro M, Frericks M, Furlong LI, Geiger R, George C, Grandits M, Ivanov-Draganov D, Kilgour-Christie J, Kiziloren T, Kors JA, Koyama N, Kreuchwig A, Leach AR, Mayer MA, Monecke P, Muster W, Nakazawa CM, Nicholson G, Parry R, Pastor M, Piñero J, Oberhauser N, Ramírez-Anguita JM, Rodrigo A, Smajic A, Schaefer M, Schieferdecker S, Soininen I, Terricabras E, Trairatphisan P, Turner SC, Valencia A, van de Water B, van der Lei JL, van Mulligen EM, Vock E, Wilkinson D
Publikováno v:
Nature reviews. Drug discovery [Nat Rev Drug Discov] 2023 Aug; Vol. 22 (8), pp. 605-606.
Autor:
Palazzi X; Drug Safety Research and Development, Pfizer Inc, 445, Eastern Point Road, Groton CT, USA. Electronic address: xavier.palazzi@pfizer.com., Anger LT; Safety Assessment, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA., Boulineau T; Nonclinical Drug Safety, Boehringer Ingelheim, 900 Ridgebury Road, Ridgefield, CT, 06877, USA., Grevot A; Preclinical Safety, Novartis AG, Fabrikstrasse, Basel, Switzerland., Guffroy M; Preclinical Safety, AbbVie, 1 North Waukegan Road, R46G/AP13A-3, North Chicago, IL, 60064, USA., Henson K; Preclinical Safety, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA., Hoepp N; Nonclinical Drug Safety, Merck and Co., Inc., Rahway, NJ, USA., Jacobsen M; Clinical Pharmacology and Safety Sciences, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, UK., Kale VP; Nonclinical Safety, Bristol Myers Squibb, 1 Squibb Dr, New Brunswick, NJ, 08901, USA., Kreeger J; Non-Clinical Safety, GSK, 1250 S. Collegeville Rd, Collegeville, PA, USA., Lane JH; Translational Safety & Bioanalytical Sciences, Amgen, Inc., 1 Amgen Center Dr, Thousand Oaks, CA, 91320, USA., Li D; Global Biometrics & Data Management, Pfizer Inc, 445, Eastern Point Road, Groton CT, USA., Muster W; Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070, Basel, Switzerland., Paisley B; iBAR ADMET, Eli Lilly and Company, 893 Delaware St, Indianapolis, IN, USA., Ramaiah L; Preclinical Sciences and Translational Safety, Johnson & Johnson, 1400 McKean Road, PO Box 776, Spring House, PA, 19477, USA., Robertson N; Non-Clinical Safety, GSK, Gunnels Wood Road, Stevenage, SG1 2NY, UK., Shultz V; Nonclinical Development, Organon, 4000 Chemical Rd, Suite 500, Plymouth Meeting, PA, 19462, USA., Steger Hartmann T; Investigational Toxicology, BAYER AG, Pharmaceuticals, Muellerstrasse 178, 13342, Berlin, Germany., Westhouse R; Toxicology and Pathology, Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, USA.
Publikováno v:
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 Jun; Vol. 150, pp. 105632. Date of Electronic Publication: 2024 Apr 27.
Publikováno v:
Frontiers in Pharmacology; 2023, p1-16, 16p
Autor:
Gurjanov A; Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com., Vieira-Vieira C; Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany., Vienenkoetter J; Bayer Research & Development, Pharmaceuticals, Pathology and Clinical Pathology, Wuppertal, Germany., Vaas LAI; Bayer Research & Development, Pharmaceuticals, Research & Pre-Clinical Statistics Group, Berlin, Germany., Steger-Hartmann T; Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany.
Publikováno v:
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 Mar; Vol. 148, pp. 105592. Date of Electronic Publication: 2024 Feb 22.
Autor:
Golden E; Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Allen D; Inotiv, Inc., Morrisville, NC, USA., Amberg A; Sanofi, Preclinical Safety, Frankfurt, Germany., Anger LT; Genentech Inc., South San Francisco, CA, USA., Baker E; Physicians Committee for Responsible Medicine, Washington, DC, USA, Baran SW; VeriSim Life, San Francisco, CA, USA., Bringezu F; Merck Healthcare KGaA, Chemical & Preclinical Safety, Darmstadt, Germany., Clark M; Charles River Laboratories, now KALOS Technologies, Philadelphia, PA, USA., Duchateau-Nguyen G; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Escher SE; Fraunhofer ITEM, Hannover, Germany., Giri V; BASF SE, Experimental Toxicology and Ecology, 67056 Ludwigshafen am Rhein, Germany., Grevot A; Novartis Institute for Biomedical Research, Novartis AG, Basel, Switzerland., Hartung T; Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.; CAAT-Europe, University of Konstanz, Konstanz, Germany., Li D; Pfizer, Global Biometrics and Data Management, Groton, CT, USA., Lotfi L; Charles River Laboratories, Boston, MA, USA, Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Snyder K; Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA., Wange R; Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA., Steger-Hartmann T; Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
Publikováno v:
ALTEX [ALTEX] 2024; Vol. 41 (2), pp. 282-301. Date of Electronic Publication: 2023 Dec 01.
Autor:
Gurjanov A; Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany., Vaas LAI; Bayer Research & Development, Pharmaceuticals, Research & Pre-Clinical Statistics Group, Berlin, Germany., Steger-Hartmann T; Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany.
Publikováno v:
ALTEX [ALTEX] 2024; Vol. 41 (4), pp. 660-665. Date of Electronic Publication: 2024 May 22.
Autor:
Hilpert J; Pharmaceuticals, Bayer AG, Berlin, Germany. jan.hilpert@bayer.com., Groettrup-Wolfers E; Pharmaceuticals, Bayer AG, Berlin, Germany., Kosturski H; Svelte® scientific GmbH, Berlin, Germany., Bennett L; Fios Genomics Ltd, Edinburgh, UK., Barnes CLK; Fios Genomics Ltd, Edinburgh, UK., Gude K; Pharmaceuticals, Bayer AG, Berlin, Germany., Gashaw I; Pharmaceuticals, Bayer AG, Berlin, Germany., Reif S; Pharmaceuticals, Bayer AG, Berlin, Germany., Steger-Hartmann T; Pharmaceuticals, Bayer AG, Berlin, Germany., Scheerans C; Pharmaceuticals, Bayer AG, Berlin, Germany., Solms A; Pharmaceuticals, Bayer AG, Berlin, Germany., Rottmann A; Pharmaceuticals, Bayer AG, Berlin, Germany., Mao G; Pharmaceuticals, Bayer AG, Berlin, Germany., Chapron C; Department of Gynecology, Obstetrics II, and Reproductive Medicine, Faculté de Santé, Faculté de Médecine Paris Centre, Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.
Publikováno v:
Drugs in R&D [Drugs R D] 2023 Sep; Vol. 23 (3), pp. 221-237. Date of Electronic Publication: 2023 Jul 09.
Autor:
Najjar A; Beiersdorf AG, Hamburg, Germany., Kramer N; Wageningen University and Research, Wageningen, Netherlands., Gardner I; Certara UK Limited, Sheffield, United Kingdom., Hartung T; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.; University of Konstanz, Konstanz, Germany., Steger-Hartmann T; Investigational Toxicology, Bayer AG, Pharmaceuticals, Berlin, Germany.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2023 Aug 02; Vol. 14, pp. 1257423. Date of Electronic Publication: 2023 Aug 02 (Print Publication: 2023).
Autor:
Steger-Hartmann T; Investigational Toxicology, Bayer AG, Pharmaceuticals, 13353 Berlin, Germany. Electronic address: thomas.steger-hartmann@bayer.com., Kreuchwig A; Investigational Toxicology, Bayer AG, Pharmaceuticals, 13353 Berlin, Germany., Wang K; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland., Birzele F; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland., Draganov D; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland., Gaudio S; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland., Rothfuss A; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland.
Publikováno v:
Drug discovery today [Drug Discov Today] 2023 Aug; Vol. 28 (8), pp. 103642. Date of Electronic Publication: 2023 May 26.